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1 ABKÜRZUNGSVERZEICHNIS 
 
AA    Amino Acids 
BCAA    Branched-chain amino acids 
BMI    Body Mass Index 
CD    Celiac disease 
CHOP    Childhood Obesity Project  
HLA    Human leukocyte antigen 
HP    Higher protein content infant formula 
LP    Lower protein content infant formula 
MS     Mass spectrometry  
NMR     Nuclear magnetic resonance  
RCT     Randomized controlled trial  
RF    Random forest  
Publikationsliste 
 
Dissertation Franca F. Kirchberg  2 
2 PUBLIKATIONSLISTE 
Diese Dissertation basiert auf folgenden Veröffentlichungen: 
 
Veröffentlichung I: 
Investigating the early metabolic fingerprint of celiac disease - a prospective approach. Kirchberg 
FF, Werkstetter KJ, Uhl O, Auricchio R, Castillejo G, Korponay-Szabo IR, Polanco I, Ribes-Koninckx C, 
Vriezinga SL, Koletzko B, Mearin ML, Hellmuth C. J Autoimmun. 2016 Aug;72:95-101. 
 
Veröffentlichung II: 
Dietary protein intake affects amino acid and acylcarnitine metabolism in infants aged 6 months.  
Kirchberg FF, Harder U, Weber M, Grote V, Demmelmair H, Peissner W, Rzehak P, Xhonneux A, 
Carlier C, Ferre N, Escribano J, Verduci E, Socha P, Gruszfeld D, Koletzko B, Hellmuth C; European 
Childhood Obesity Trial Study Group. J Clin Endocrinol Metab. 2015 Jan;100(1):149-58.  
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3 SUMMARY 
Background:  
The hypothesis of early programming states that stimuli applied during the critical or sensitive 
period can program long-term the structure or function of the organism. Metabolomics is a useful 
tool to investigate alterations in molecular pathways related to health outcomes. In this doctoral 
thesis, I used metabolomics data to examine the early programming of two different diseases, 
namely celiac disease (CD) and obesity. 
Methods:  
The PreventCD study is a large European study including children at high genetic risk for CD. 
Metabolomics data was available of 4 months old infants that have not yet been introduced to 
gluten. I investigated whether there existed a characteristic metabolic profile in infants developing 
CD during childhood, whether the genotype influenced the metabolic profile, or whether the 
metabolite species were predictive for the age of CD development. Regarding obesity, I used data 
from the 6 month visit of the CHOP study which is a randomized controlled European trial. Infants 
were randomized to a lower or higher protein content infant formula and those of the HP group 
were found to be at higher risk for obesity at school age. At 6 months of age, metabolomics 
analyses were performed and I used thus data to examine the programming effect of the higher 
protein formula milk.  
Results:  
Regarding CD, evidence was scarce and, based on our results, we could not conclude on a 
programmed metabolism in 4 months old children developing CD in childhood. Our results 
furthermore showed that the HLA-genotype had no influence of the infants at this age. As the 
infants had not been exposed to the triggering factor gluten, we suggested that future studies 
should target infants after the introduction of gluten. Concerning the comparison of the metabolite 
profile of the intervention groups of the CHOP study, we could show that the branched-chain 
amino acids (BCAA) were markedly increased whereas long-chain acylcarnitines were decreased in 
the infants receiving the HP formula milk. We also found evidence for a saturation of the BCAA 
catabolism. Thus, the insulinogenic amino acids (AA) and AA promoting IGF-1 secretion might be 
responsible for the adverse programming of HP children. Furthermore, the decreased beta-
oxidation as evidence by decreased acylcarnitine levels in HP children might be linked to the higher 
leucine levels. 
 
Zusammenfassung 
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Conclusion:  
Metabolomics in epidemiology offers the unique opportunity to perform hypothesis driven 
mechanistic analyses and detailed results as delivered by metabolomics studies will enable the 
target development of interventional strategies.  
 
4 ZUSAMMENFASSUNG 
Ziele: 
Das Konzept von ‚Early Programming‘ beruht auf der Hypothese, dass bestimmte Stimuli im 
frühkindlichen Alter langfristige Auswirkungen auf den Organismus haben können. Metabolomics 
ist eine Wissenschaft, die sich zur Untersuchung von Krankheiten und den damit einhergehenden 
Veränderungen im Stoffwechsel als sehr hilfreich erwiesen hat. In dieser Doktorarbeit verwendete 
ich Metabolomics um das Early Programming zweier spezifischen Krankheiten,  nämlich Zöliakie 
und Adipositas, zu beleuchten. 
Methoden: 
Die PreventCD Studie ist eine europäische Studie, die Kinder mit hohem genetischem Risiko auf 
Zöliakie einschließt.  Im Alter von 4 Monaten, vor der Einführung von Gluten, wurden 
Metabolomics Messungen bei den Kindern durchgeführt. Anhand dieser Daten konnte ich drei 
Fragestellungen beantworten: gibt es bereits im Alter von 4 Monaten ein charakteristisches 
metabolisches Profil in Kindern, die in ihrer Kindheit Zöliakie entwickeln? Hat der HLA-genotyp 
einen Einfluss auf das Metabolom? Lässt das 4-monats Metabolom Rückschlüsse auf das Alter bei 
Ausbruch von Zöliakie zu? Im Falle von Adipositas nutzte ich Daten der CHOP Studie, eine 
europäische randomisierte Studie, in der die Kinder zufällig der Zufuhr einer proteinreichere (HP) 
oder proteinärmere (LP) Säuglingsmilch zugeordnet wurden. In dieser Studie konnte die Early 
Protein Hypothese, welche besagt dass hohe Proteinzufuhr im frühkindlichen Alter das Risiko für 
spätere Adipositas erhöht, bestätigt werden. Im Rahmen dieser Arbeit untersuchte ich den Effekt 
der Säuglingsnahrung auf den Metabolisms im Alter von 6 Monaten. 
Ergebnisse: 
Im Falle von Zöliakie konnten wir kein Early Programming feststellen. Der Metabolismus in den 4 
Monate alten Kindern ließ keinen Schluss über einen möglichen Zöliakie Ausbruch zu und auch der 
Genotyp hatte keinen nachweisbaren Effekt auf das Metabolom. Nachdem die Kinder noch kein 
Gluten zu sich genommen hatten, sollten spätere Studien speziell Kinder nach der Einführung von 
Gluten betrachten. Was Adipositas betrifft, so zeigte der Gruppenvergleich der randomisierten 
Zusammenfassung 
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Gruppen, dass vor allem die verzweigtkettigen Aminosäuren (AA) sowie deren Abbauprodukte, die 
kurzkettigen Acylcarnitine, in der HP Gruppe erhöht waren. Des Weiteren fanden wir Hinweise auf 
eine Sättigung des BCAA Katabolismus. Damit könnten die insulinogenen AA oder AA, welche die 
IGF-1 Sekretion erhöhen, für den programming Effekt der proteinreicheren Säuglingsmilch 
verantwortlich sein. Außerdem waren die langkettigen Acylcarnitine in den HP Kindern niedriger 
konzentriert, was auf eine geringere Fettverbrennung deuten könnte. Möglicherweise könnte 
Leucin das Bindeglied zwischen den beiden Beobachtungen sein. 
Schlussfolgerungen: 
Die Anwendung von Metabolomics in der Epidemiologie bietet die einzigartige Möglichkeit um 
hypothesengesteuerte Studien durchzuführen und Krankheiten auf molekularer Ebene zu 
untersuchen und zu charakterisieren. Diese detaillierten Ergebnisse werden gezielte und 
personalisierte Behandlungen ermöglichen. 
  
Einleitung 
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5 EINLEITUNG 
During the last half of the 20th century, more and more evidence accumulated supporting the idea 
of early programming: It is believed that pre- and perinatal factors influence the risk for adverse 
adult health outcomes [1, 2]. In the early 60ies, Widdowson and McCance provided first evidence 
for the long term programming of development and adult body size by postnatal 
undernourishment in rats [3, 4]. In 1975, Dörner first used the term ‘programming’ in order to 
describe the findings on early lifetime factors modulating later health. In his article, he suggested 
that homeostatic variables, comprising metabolites, hormones, and neurotransmitters, during the 
critical periods in early life were capable to pre-program brain development, functional disorders, 
and diseases [5]. Important insights were furthermore added by research on the consequences of 
the Dutch famine caused by the German blockade of Holland at the end of World War II which used 
the historical Dutch Famine cohort study including 300,000 19-years old men. These analyses 
revealed different obesity rates in the offspring according to the exposure of the famine – whether 
it was during the first or last trimester of their mothers pregnancy [6]. Later, in 1989, Barker et al. 
brought the idea of the early programming concept back to live. Using data from the Hertfordshire 
Cohort Study, they found that anthropometric measures at birth were related to later morbidity 
and mortality [7]. Again three years later, in 1992, Hales and Berker [8] coined the ‘thrifty 
phenotype hypothesis’ stating that poor fetal and post-natal nutrition was detrimental to the 
development and function of organs leading to long-lasting alterations in growth and function of 
tissues. During the same period, the term ‘programming’ reappeared in science. This time, 
however, it referred to the programming of long-term health by nutrition [9]. Since then, based on 
the results of epidemiological studies, much research has dealt with early life factors and their 
impact on later health outcomes. The underlying idea is that a stimulus or insult that is applied 
during the sensitive or critical period can program long-term or lifetime structure and function of 
the organism [10, 11]. Nowadays, this concept is described as the ‘developmental origins of health 
and disease hypothesis’ [1] and the research in this area is promoted by the International Society 
for Developmental Origins of Health and Disease which was established in 2003 [12].  
Early programming furthermore strongly associates with the approaches of personalized medicine. 
The fact that certain treatment strategies help some patients while they are ineffective for others, 
urge research to develop personalized treatment strategies and to examine the causes for the 
ineffectiveness in these patients. The numbers published by the Personalized Medicine Coalition 
clearly demonstrate the need for individualized medicine: For instance, 43% of the patients having 
diabetes are not responding to the given treatment. In cancer, this percentage even rises up to  
Einleitung 
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75% [13]. It is believed that different underlying mechanisms leading to the same phenotype are 
among the reasons for the ineffectiveness of certain treatments in some patients. As in the case of 
early programming, the challenge lies then in the characterization of these altered metabolic 
pathways.  
The high-throughput omics-sciences (e.g. genomics, transcriptomics, metabolomics) present a 
powerful tool to dissect the molecular causes and hence the programming of an organism. The 
study of the dynamics of biological networks will path the way for personalized disease diagnosis 
and treatment approaches [14]. The neologism ‘omics’ refers to sciences aiming at a complete 
quantification and characterization of pools of biological molecules “that translate into the 
structure, function, and dynamics of an organism or organisms” [15].  
Metabolomics 
Metabolomics is a very recent addition to the omics-family and it has enjoyed a growing popularity 
over the last 15 years [16]. It is the science of very small molecules (typically < 1500 Da), the so 
called metabolites, present in a sample, usually cells, tissue, or body fluids. The quantitative 
complement of all the metabolites is called metabolome [17-19]. As of June 2017, there were 
74,461 metabolites listed in the Human Metabolome Database [20]. The sample which is used for 
the determination of metabolites depends on several factors: While the sample of choice should in 
first instance depend on the research question, the options might be limited as biopsies are not 
obtainable due to ethical concerns based on the lack of direct benefit for the patient and risks 
associated with any surgical procedure [21]. Instead, in clinical studies blood or urine are usually 
sampled as they are considered minimally invasive and this opens up the possibility to perform 
metabolic phenotyping on large populations [22]. With respect to the measurement concentrations 
of the metabolites in the sample, there are two different approaches, namely targeted and non-
targeted metabolomics. Targeted metabolomics, which is used in this thesis, refers to a method in 
which a pre-defined set of metabolites is measured; the most common analytical techniques are 
nuclear magnetic resonance (NMR) and mass spectrometry (MS). Compared to NMR, MS, and 
especially triple quadrupole MS, yield highly sensitive, robust, and quantitatively reliable 
measurements of metabolites [23].  
The complete metabolite profile obtained is then used for the characterization of a certain 
physiological state: Metabolites are intermediates or products of the metabolism and “their levels 
can be regarded as the ultimate response of biological systems to genetic or environmental 
changes” [18]. Thus, subtle changes in the genome, epigenome, and proteome may be reflected at 
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the metabolome level and the changes in concentrations may be indicative for pathologic changes 
before they can be seen on a static histologic slide. Due to the possibility to characterize the 
metabolic state of a person based on his metabolic profile, metabolomics is a promising tool in 
biomarker research and personalized medicine [24, 25]. The number of metabolomics research 
studies for biomarker identification published over the past 10 years has increased exponentially 
[16]. In 2016, 750 matches on research articles containing the keywords ‘metabolomics’ and 
‘biomarker’ are found on PubMed. These studies can further be grouped into three categories: 
While the major group of metabolomics studies is dedicated to the investigation of altered 
pathways and underlying mechanisms of diseases, somewhat fewer studies are using 
metabolomics data for diagnostic purposes or focusing on the translation of biomarkers from the 
lab to the clinic [16].  
Outline of this doctoral thesis 
In this work, I aim at investigating the early pathogenesis celiac disease (CD) and obesity. Previous 
studies have outlined the changes in the metabolism coming along with these diseases and there is 
furthermore evidence for an early programming of the risk for the development of CD and obesity 
[10, 26-29]. Here, I use metabolomics data in order to investigate in detail if there are early 
changes in metabolism related to an increased disease risk later in life, and, if so, what pathways 
are involved. Though the ultimate goal of my research is the same for both diseases, there are 
methodological differences: While the analysis on the pathogenesis of CD is based on prospective 
data, the investigations regarding obesity are based on a randomized controlled trial (RCT). Both 
study designs are suitable for the investigation of early programming effects, but there are subtle 
though important differences in the interpretation of the results. In the prospective design, there 
was no focus on one specific programming factor. By looking at the metabolome in relation to a 
later CD development, we may have detected any early programming factor affecting the 
metabolism but identification of these factors might have been difficult if not impossible. In 
contrast, the RCT enables the close examination of one specific factor, in this case high protein 
intake, and its programming effect of the metabolism. Therefore, a clear characterization of the 
programming effect and its metabolic consequences is possible. The two studies, research 
questions, and statistical approaches will be outlined in more detail in the following.  
Publication 1 – Early Programming of Celiac Disease 
CD is among the most common food intolerances. Its prevalence among the general population is 
estimated approximately 1% [30]. The gastro-intestinal disorder is characterized by chronic 
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inflammation of the small intestinal mucosa leading to villous atrophy. CD is triggered by gluten 
and other prolamines contained in wheat, rye, barley, and other cereals in genetically susceptible 
individuals [31]. Only adherence to a strict gluten-free diet should reverse the damage to the small 
intestine and allow for normalization of digestion and nutrient absorption. The PreventCD study 
has been designed to investigate whether an early introduction of small quantities of gluten were 
beneficial with regard to reducing the incidence of CD among children from high-risk families. In 
this RCT, infants were randomized to receive 100 mg of immunologically active gluten daily or 
placebo from 16 to 24 weeks of age. The study provided evidence that an early exposure to gluten 
did not alter the risk of CD by 3 years of age. Furthermore, breastfeeding was not found to have 
positive effects on reducing the risk for CD [32]. This data offers excellent opportunities to examine 
the early mechanisms of CD. At 4 months of age, we had blood samples from the infants. Using 
direct infusion mass spectrometry and liquid chromatography-mass spectrometry, we measured 
amino acids and polar lipid concentrations (acylcarnitines, lysophosphatidylcholines, phosphatidyl-
cholines, and sphingomyelins). The longitudinal setup of the study and the long follow-up up to the 
age of 8 years provided the perfect basis for a prospective examination of the metabolome of 
these children long before manifestation of the disease. The hypothesis of an altered metabolism 
from very early age on is based on the results of Bertini et al. [26] and Bernini et al. [27] who 
provided evidence for an altered plasma metabolic profile in CD patients. CD patients were found 
to have a different plasma metabolic profile compared to their healthy controls: with respect to 
malabsorption, to the energy metabolism, and to alterations in gut microbiome and/or intestinal 
permeability [26]. Bernini et al. then provided evidence that the alterations in the metabolism of 
CD patients were preceding the development of small intestinal villous atrophy [27]. They 
compared healthy subjects with those having potential CD (patients with positive CD serology in 
the absence of any apparent intestinal damage) or overt CD (patients with villous atrophy). The 
metabolic profile of patients with potential CD was very similar to the one of patients with overt 
CD. The authors conclude that alterations of the enterocytes and metabolism arise before the 
observable macroscopic modification of intestinal mucosa [27]. Both research studies were 
performed on adults. The first publication of this doctoral thesis builds on the findings from Bertini 
et al. and Bernini et al.: I hypothesize that these changes in metabolism can already be seen in very 
young infants prior to the introduction of gluten. If this was true, it would mean that the 
programming of children towards a higher disease risk would take place prior to the age of 4 
months, which is the age of the children at blood withdrawal. I aimed at answering three 
questions: 1) Is there a characteristic metabolic trait in the blood of 4 months old infants 
developing CD later in life? 2) Does the metabolite profile at 4 months of age contain information 
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on the age of CD onset? 3) Does the human leukocyte antigen (HLA) genotype influence the 
metabolism of the children at 4 months of age? Especially research question 2) makes use of the 
prospective design by analyzing the ‘time to event’. Using cox-proportional hazards models, it is 
possible to quantify the effect of a covariate (in this case the metabolite concentration) on the risk 
for CD development. In other words, the metabolite concentrations are considered risk factors and 
their levels in early life are used to predict the child’s risk for CD development. However, although 
the literature suggests that metabolic alterations precede the onset of CD, we could not find any 
metabolic alterations in 4 months old children developing CD in childhood, preceding the 
introduction of gluten, nor did we find that the metabolic profile was predictive for the age at CD 
diagnosis. Also regarding the HLA genotype, we did not find metabolic differences across the 
genotypes [33]. 
Publication 2 – The Early Protein Hypothesis on the Programming of Obesity 
The second aspect I investigated more closely is the etiology and pathogenesis of obesity by means 
of metabolomics analysis in an interventional trial. A high body-mass index (BMI) ranges among the 
top ten largest contributors to global deaths and disability-adjusted life-years among Level 3 [34]. 
The obesity prevalence rose from 3,2% in 1975 to 10,8% in 2014 in men and from 6.4% to 14.9% in 
women [35]. This rise furthermore represents a huge economic burden for societies: Obesity was 
estimated to have a global economic impact of roughly US$ 2.0 trillion – an amount roughly 
equivalent to the global impact from smoking or armed violence, terrorism, and war [36, 37]. In 
children, obesity is “one of the most serious public health challenges of the 21st century” [38]. In 
the 1990s, first evidence arose from epidemiological studies that a higher early protein intake 
might increase the risk for later obesity: Using data from the French ELANCE longitudinal study, 
Rolland-Cachera et al. [39] investigated the effect of nutritional intakes at age of 2 years on 
anthropometric measurements and showed that protein intake was the only nutrient that was 
associated to body fatness at 8 years of age. This positive relationship was confirmed in several 
other studies [40-43]. Based on these observations, the ‘early protein hypothesis’ was postulated 
[44] and the Childhood Obesity Project (CHOP) was launched [45]. According to the ‘early protein 
hypothesis’, an increased protein intake exceeding the infant’s requirement, stimulates the 
secretion of insulin and insulin like growth factor 1 which then enhances early growth and 
adipogenic activity [46]. The CHOP study was designed to test this hypothesis. In this multicenter 
European study, infants of parents who decided to formula-feed their child were randomly 
assigned to receive cow milk–based infant and follow-on formula with lower (1.77 and 2.2 g 
protein/100 kcal, respectively) or higher (2.9 and 4.4 g protein/100 kcal, respectively) protein 
Einleitung 
 
Dissertation Franca F. Kirchberg  11 
contents for the first year. The primary endpoints of this study were length and weight-for-length z 
scores at the age of 2 years. While length did not differ between the formula groups, infants of the 
higher protein (HP) group had an average weight-for-length z score elevated by 0.20 standard 
deviation compared to the lower protein (LP) group [45]. Also at school age, children of the HP 
group were at higher risk to be overweight or obese: The risk of becoming obese in the HP group 
was 2.43 times higher than for children of the LP group [47]. However, it has to be noted that the 
CHOP study is unique in the sense that it is the only RCT assessing the infant’s outcomes after 
infancy. Therefore, a recent review concluded that there is insufficient evidence on the effect of 
different protein intakes on the children’s growth, body composition, and later risk of overweight 
and obesity in the long term and that further studies replicating the findings of the CHOP study are 
needed before certainty on the effects of early protein can be attained [48]. One important step in 
the investigation of this topic is the examination of the underlying mechanistic pathways. An 
understanding of these pathways will help to classify the results observed in the clinical trials. In 
my second publication of this doctoral thesis, I therefore aimed at closing the gap on the 
mechanistic backgrounds of the effects of the higher protein content in the formula milk. We had 
blood samples of the infants when they were 6 months of age. We measured plasma amino acid 
and acylcarnitine concentrations by liquid chromatography coupled to tandem mass spectrometry. 
Based on this data, I investigated the differences in the metabolism of the infants. I used linear 
mixed models to test for different mean concentration of the metabolites between the two 
intervention groups. These models are required to account for the correlation structure arising 
from the multi-centric study design. I furthermore used random forest (RF) to analyze the 
differences in the metabolome in the multivariate context. The main finding was on the branched-
chain amino acids (BCAA) and their degradation products, the short-chain acylcarnitines, which 
were highly elevated in the HP group compared to the LP group. We speculate that this is a result 
of the BCAA escaping the first-pass liver metabolism and that leucine, which is an insulinogenic 
amino acid, might relate the higher protein intake in infancy with the later increased risk for 
obesity in childhood. We furthermore found an indication for a saturation of the BCAA degradation 
capacity which might increase the detrimental programming effect [49].  
Conclusion 
This doctoral thesis contributes to our understanding of the early programming of CD and obesity 
and the role that metabolomics plays in this research area. Based on previous findings, I further 
investigated the pathogenesis of these two diseases at the molecular level. The results add 
knowledge on the early programming of the diseases and indicate new directions and starting 
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points for further hypothesis driven research. In the case of CD, my work suggests to focus on older 
children after gluten was introduced or even later in childhood as alterations might occur only 
within a shorter period before CD onset. With respect to obesity, I provide evidence that the BCAA 
might play a pivotal role in the programming of obesity but also with relation to the fatty acid 
oxidation. Targeted metabolomics, which enables the absolute quantification of known molecules 
and which was used in this thesis, proved a promising tool in hypothesis driven research. Thus, this 
work builds a basis for further studies aiming at understanding the mechanisms of the diseases in 
which targeted metabolomics will offer great possibilities and deliver insights at the molecular 
level.  
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